Luis Schwarz

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERα signaling, and provides a strong(More)
  • 1